This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $176,754 to Clemson University to conduct research on using electronic cigarettes as a harm reduction strategy among people with opioid use disorder on buprenorphine treatment. The key objectives of this 5-year grant are to: 1) Test the effect of different e-cigarette flavors on reducing combustible cigarette use, switching to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $619,175 to The Medical University of South Carolina to conduct a type 1 hybrid effectiveness-implementation trial evaluating an e-cigarette switching approach for oncology outpatients who smoke and refuse traditional tobacco treatment. The key objectives are to: 1) directly compare rates of switching to e-cigarettes versus standard care among 208 oncology outpatients; 2)...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) will provide $1,197,896 to the University of Oklahoma Health Sciences Center to study the impact of electronic nicotine delivery system (ENDS) product characteristics on use behaviors and abuse liability among young adults. The study will utilize a combination of traditional surveys and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $241,500 to Duke University to examine the use of very low nicotine content (VLNC) cigarettes as a means to improve smoking cessation outcomes among individuals with opioid use disorder and chronic pain. The research will employ a randomized design to evaluate the effects of VLNC cigarettes versus normal nicotine content cigarettes on smoking...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the effects of maternal exposure to electronic nicotine delivery system (ENDS) aerosols during pregnancy on addiction-related behaviors and neurobiological functioning in offspring. The $1,315,596 award to the Hennepin Healthcare Research Institute will fund a 5-year study using animal models to examine the impacts of...
This federal Project Grant award for $625,201 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a randomized factorial trial to evaluate the effectiveness of combining varenicline with nicotine lozenges and a smartphone medication adherence intervention to promote smoking cessation. The study aims to enroll 496 adult smokers and assess 7-day point prevalence abstinence at 26 weeks and medication adherence over the 13-week...
The National Institute on Drug Abuse (NIDA) awarded a $1,826,522 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The Medical University of South Carolina to develop and test a digital toolkit to address intimate partner violence (IPV), post-traumatic stress disorder (PTSD), and opioid use disorder (OUD) in opioid treatment programs (OTPs). The project has three aims: 1) conduct stakeholder interviews to inform the development of the digital toolkit for assessing IPV,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $265,239 to the University of North Carolina at Chapel Hill to evaluate the chemical composition and toxicity of vaping products containing novel nicotine analogs like 6-methyl nicotine. The study aims to characterize the oxidation products formed during the aerosolization of these vaping liquids and assess their toxicity in human bronchial...
This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $3,257,011 to evaluate a tobacco harm reduction strategy among clients enrolled in substance use disorder (SUD) treatment programs.
The key objectives of this 5-year study are to: 1) Assess whether switching to electronic nicotine delivery systems (ENDS) is more effective than nicotine replacement therapy (NRT) in promoting abstinence from cigarettes among SUD treatment clients; 2) Evaluate patient, provider, and organizational-level implementation outcomes of the ENDS intervention; and 3) Assess SUD treatment outcomes and engagement between the ENDS and NRT groups. The study will enroll 240 clients across 3 outpatient SUD programs in South Carolina and employ a hybrid type 1 effectiveness-implementation randomized controlled trial design. The Medical University of South Carolina, a public academic research institution, will serve as the primary awardee for this grant, which has an award date of September 15, 2024 and an ultimate completion date of May 31, 2029.